<DOC>
	<DOCNO>NCT00220571</DOCNO>
	<brief_summary>The aim study conduct patient high risk ST-segment elevation AMI admit hospital PTCA facility compare effect clinical outcome cost-effectiveness two reperfusion strategy : - Fibrinolytic therapy Abciximab half-dose Reteplase , rescue PTCA case lack reperfusion - Elective referral “ facilitate ” PTCA early administration Abciximab half dose Reteplase</brief_summary>
	<brief_title>CARESS Acute Myocardial Infarction</brief_title>
	<detailed_description>All patient ST-segment elevation AMI admit within 12 hour symptom onset screen enter study . Data patient ST-segment elevation AMI within 12 hour symptom onset meet inclusion criterion sign inform consent form enter dedicated registry .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Reteplase</mesh_term>
	<criteria>ECG STelevation ( ≥ 1mm least 2 ECG limb lead ≥ 2 mm 2 contiguous precordial lead ) AMI within &lt; 12 hour symptom onset fulfil 1 follow criterion “ high risk ” : 1 . Summation STsegment elevation depression ≥ 15 mm 12 electrocardiographic lead new onset complete leave bundle branch block ; 2 . Previous myocardial infarction ( Q non Qwave ) ; 3 . Killip Class 2 3 ; 4 . LV ejection fraction transthoracic ultrasound &lt; 40 % . 1 . Inability provide informed consent ; 2 . Age &gt; 75 year 3 . CABG PCI procedure past history involve infarctrelated artery ; 4 . Participation another study investigational drug device within previous 30 day ; 5 . Concomitant noncardiac disease likely limit longterm prognosis ( e.g . cancer ) ; 6 . Cardiogenic shock ( hypotension Systolic Blood Pressure ( SBP ) &lt; 90 mmHg tachycardia &gt; 100 beat / min , due hypovolemia require inotropic support balloon counterpulsation ) ; 7 . Need concomitant major surgery ( e.g . valve surgery resection aortic leave ventricular aneurysm , carotid endarterectomy , abdominal aortic aneurysm surgery , congenital heart disease etc ) ; 8 . Severe hepatic disease ; 9 . Patients acute chronic renal impairment ( serum creatinine &gt; 2.0 mg % 200 mg/l creatinine clearance &lt; 30 ml/min ) ; 10 . Transmural MI different location within previous week ; 11 . Previous administration thrombolytic within 7 day ; 12 . Intolerance contraindication ASA Clopidogrel ; 13 . Known leucopenia , define leukocyte count &lt; 3.500 White Blood Cells ( WBC ) /ml 14 . Known neutropenia , define &lt; 1000 neutrophil / ml ; 15 . Known thrombocytopenia ( &lt; 100.000 platelet / ml ) ; 16 . Documented active peptic ulcer upper gastrointestinal bleeding within previous 6 month ; 17 . Previous hemorrhagic stroke ; 18 . Previous ischemic cerebrovascular event within 3 month ; 19 . Intracranial neoplasm ; 20 . Recent major surgery risk bleeding ; 21 . Episodes uncontrolled hypertension ( &gt; 180/110 mmHg despite treatment ) past 2 year ; 22 . Administration oral anticoagulant within previous 7 day unless INR ≤ 1.2 ; 23 . Severe recent trauma ; 24 . Known possible pregnancy ; 25 . Absence suitable vascular access ( diffuse peripheral arterial disease ) ; 26 . Basal ECG change make identification STsegment elevation impossible ( i.e . : ventricular activation artificial pacemaker , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>AMI</keyword>
	<keyword>stent</keyword>
	<keyword>PTCA</keyword>
	<keyword>abciximab</keyword>
	<keyword>reteplase</keyword>
	<keyword>combo therapy</keyword>
</DOC>